Average Insider

Where insiders trade, we follow

$CYBN
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
Healthcare
Sector
Biotechnology
Industry
Eric So
CEO
50
Employees
$8.28
Current Price
$413.02M
Market Cap
52W Low$4.81
Current$8.2858.7% above low, 41.3% below high
52W High$10.72

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys11$1,208,900.00100,000All Buys
Sells00--
2 weeksBuys24$4,551,332.00385,000All Buys
Sells00--
1 monthBuys24$4,551,332.00385,000All Buys
Sells00--
2 monthsBuys24$4,551,332.00385,000All Buys
Sells00--
3 monthsBuys24$4,551,332.00385,000All Buys
Sells00--
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Sep 4, 2026
So Eric H. L.
Director
Purchase100,000$12.09$1,208,900.00View Details
Sep 3, 2026
Glavine Paul
Chief Growth Officer
Purchase100,000$11.78$1,178,280.00View Details
Sep 1, 2026
So Eric H. L.
Director
Purchase95,000$11.80$1,121,475.00View Details
Aug 31, 2026
Glavine Paul
Chief Growth Officer
Purchase90,000$11.59$1,042,677.00View Details

Upcoming Earnings

Scheduled earnings reports
No upcoming earnings scheduled

Past Earnings

Historical earnings results
No earnings data in the last 3 months. Sign up free to see 12 months of history.
Version: v26.7.3